Bio-Rad - Preparing for a Stress-free QC Audit

Changing Analyzers Without Losing Specialized Protein Testing

A multi-platform turbidimetric portfolio can help laboratories preserve specialized protein testing capabilities when moving to a new analytical environment.

When the analyzer changes, what happens to the test menu?

For laboratories planning a transition away from the Beckman Coulter IMMAGE® 800 protein chemistry analyzer, replacing the instrument is only part of the challenge.

The more practical question is often: what happens to the specialized protein assays already incorporated into the laboratory’s diagnostic menu?

IMMAGE 800 has long provided a dedicated nephelometric environment for specific protein testing. When laboratories move to a new analyzer, maintaining access to clinically relevant assays can become an important consideration alongside throughput, automation, connectivity and overall platform performance.

Some laboratories may remain within the Beckman Coulter ecosystem and migrate towards AU/DxC clinical chemistry systems. Others may use the transition to reassess their analytical environment and adopt a different clinical chemistry platform.

In either case, changing instrumentation should not necessarily mean giving up specialized testing capabilities.

261117 CLI Changing Analyzers 1

One portfolio. Multiple analytical environments.

Trimero Diagnostics has developed a portfolio of turbidimetric assays for specialized protein testing designed for use across a broad range of automated clinical chemistry systems.

Applications are available for widely used platforms including Atellica® CH, Alinity c, Cobas® c, AU® series, Optilite®, BA400 & BA200 Biosystems, and Mindray series among others, depending on the individual assay, analyzer configuration and market availability.

This multi-platform approach gives laboratories greater flexibility when planning an instrument transition.

A laboratory moving from IMMAGE 800 to Beckman Coulter AU/DxC systems can continue exploring Trimero assays within its new analytical environment. A laboratory choosing another compatible chemistry platform can retain the same possibility.

The principle is simple:

change the analyzer without automatically changing the specialized diagnostic capabilities available to your laboratory.

For laboratories managing multiple sites or heterogeneous instrument fleets, this flexibility can also make specialized protein testing less dependent on a single analyzer family.

Specialized protein testing across key clinical areas

Trimero’s turbidimetric portfolio currently comprises 16 assays spanning several clinically relevant areas of laboratory medicine.

For gammopathies and protein disorders, the portfolio includes Kλoneus® Free Light Chains, total Kappa and Lambda light-chain assays, and IgD and IgE assays. With serum and urine options available for selected assays, the portfolio supports laboratory workflows for the investigation and follow-up of protein disorders, according to the intended use of each assay.

For renal glomerular and tubular assessment, the range includes Cystatin C, Beta-2 Microglobulin, Alpha-1 Microglobulin and Retinol Binding Protein, with serum and/or urine applications depending on the analyte.

The complement and immunology portfolio includes assays for C1 Inhibitor, C1q, C5 and Factor B, supporting the investigation of selected complement-related and immunological disorders.

The portfolio also includes Serum Amyloid A for inflammatory assessment, soluble Transferrin Receptor for iron-status related investigation and Hemopexin, a heme-binding protein relevant to the laboratory assessment of intravascular haemolysis and related conditions.

Together, these assays allow laboratories to introduce or maintain specialized protein testing within routine automated analytical environments.

Reducing uncertainty during platform transition

Changing an analyzer can affect much more than instrumentation. Laboratories may need to review assay availability, verification requirements, workflows, staff training and the continuity of tests requested by clinicians.

A multi-platform reagent strategy cannot eliminate every aspect of that transition, but it can provide greater flexibility when deciding which analytical environment best fits the laboratory.

For Trimero customers, the objective is to make the analyzer decision less dependent on the availability of a single specialized protein platform.

Change your analyzer, not your specialized protein testing capabilities. Trimero’s turbidimetric portfolio supports continuity across compatible clinical chemistry platforms.

261117 CLI Changing Analyzers 2

Explore the portfolio for your platform

If your laboratory is reviewing its analytical environment, this may be a good time to assess which specialized protein tests should remain or could be added to your diagnostic menu.

Explore Trimero Diagnostics’ turbidimetric portfolio and available analyzer applications:
https://3diag.com/spa/l3_turbidimetry.php

For platform-specific application information, assay availability or support planning your transition, contact Trimero Diagnostics or your local authorized distributor.

Request information

Get in touch directly with the above supplier

Your email address will not be communicated to any third party other than the above supplier for the purpose of fulfilling this enquiry. For more information: read our privacy policy.

I’m interested in:

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.